The immune system's inflammatory response is governed not just by the molecules that ignite inflammation, but equally by those that extinguish it. Interleukin-1 receptor antagonist (IL-1Ra)¹¹ Interleukin-1 receptor antagonist (IL-1Ra)
The natural protein inhibitor of IL-1α and IL-1β — it occupies the IL-1 receptor without triggering signaling, acting as a competitive brake on the entire IL-1 cytokine axis is one of the most important of these brakes. Encoded by the IL1RN gene on chromosome 2q14.1, IL-1Ra is the direct target of anakinra, a recombinant form of the protein used clinically in rheumatoid arthritis and systemic autoinflammatory diseases. The rs2234663 polymorphism is a variable number tandem repeat (VNTR)²² variable number tandem repeat (VNTR)
A type of DNA polymorphism where a short DNA sequence is repeated a different number of times in different individuals; this particular VNTR consists of an 86 base-pair repeat unit in intron 2 of IL1RN, present in 2, 3, 4, 5, or 6 copies depending on the allele located in the second intron of IL1RN. The most clinically relevant distinction is between the A1 allele (4 copies of the 86bp repeat — the common form) and the A2 allele (2 copies — the shorter, risk-associated form). Together these two alleles account for over 95% of chromosomes studied.

The Mechanism

The intron 2 VNTR does not alter the IL-1Ra protein sequence, but it does alter how the gene is regulated. The repeated 86bp units contain binding sites for transcription factors and splicing regulators³³ binding sites for transcription factors and splicing regulators
These include sites resembling SP1, TCF, and other regulatory elements; the number of repeat copies changes the chromatin architecture and accessibility of the intron 2 region, influencing alternative transcript initiation and splicing. IL1RN produces four distinct protein isoforms through alternative promoter usage and splicing: the secreted form (sIL-1Ra, the dominant circulating antagonist) and three intracellular forms (icIL-1Ra I, II, and III). The A2 allele alters the balance between these isoforms in ways that are cell-type and context-dependent. The net effect in inflammatory tissues — particularly mucosal surfaces such as gastric mucosa and periodontium — is an insufficient IL-1Ra response that allows IL-1β-driven inflammation to persist and amplify unchecked.

This is consistent with a broader principle in IL-1 biology: the critical parameter is not IL-1β concentration alone, but the IL-1β:IL-1Ra ratio⁴⁴ IL-1β:IL-1Ra ratio
The relative amounts of the pro-inflammatory IL-1β and its endogenous antagonist IL-1Ra. When IL-1Ra production is insufficient relative to the IL-1β signal, even modest IL-1β levels can drive sustained tissue-destructive inflammation. The A2 allele shifts this ratio toward greater effective IL-1β activity at sites where it matters most.

The Evidence

The landmark connection between the IL1RN VNTR and gastric cancer was established by El-Omar et al. 2000⁵⁵ El-Omar et al. 2000
Nature 404:398-402; case-control and cohort studies showing IL-1 cluster polymorphisms associated with hypochlorhydria after H. pylori infection and gastric cancer development in Nature, demonstrating that individuals with certain IL-1 cluster variants who become infected with H. pylori develop more extensive corpus gastritis, progressing to hypochlorhydria and atrophy — the recognized precancer sequence. H. pylori activates IL-1β production in the gastric mucosa; the IL-1RN VNTR modulates how effectively IL-1Ra can contain this response. In a Brazilian study of 675 individuals, Oliveira et al. 2012⁶⁶ Oliveira et al. 2012
Mol Biol Rep 39:7617; 229 gastritis cases, 200 gastric cancer cases, 246 controls found the IL-1RN A2 allele associated with gastric cancer (OR=3.04, p<0.01) and chronic gastritis (OR=2.32, p=0.02) in a recessive model. An Omani study of 118 gastric cancer patients confirmed A2 association (OR=2.2, p=0.04), amplifying to OR=3.5 in H. pylori-positive individuals.

In the periodontium, Ding et al. 2012⁷⁷ Ding et al. 2012
Arch Oral Biol 57:585; meta-analysis of 19 studies, 2,011 chronic periodontitis cases and 1,719 controls found the VNTR polymorphism marginally associated with chronic periodontitis overall (OR=1.47, p=0.05), but strongly associated with severe disease (OR=4.02, 95% CI 1.84–8.80, p<0.0005). This dose-dependent severity effect is characteristic of a variant that shifts the threshold for inflammation resolution rather than simply turning on disease.

For systemic lupus erythematosus, a Bulgarian case-control study (55 SLE patients, 112 controls) found Kamenarska et al. 2014⁸⁸ Kamenarska et al. 2014
Dermatol Res Pract; OR=2.5, 95% CI 1.2–5.4 for A2 allele in SLE patients. For COPD, a systematic review and meta-analysis of 26 studies identified IL1RN rs2234663 as showing a strong association with COPD susceptibility among interleukin gene variants — consistent with the variant's role in modulating inflammatory persistence in chronically exposed airways. For bone infections, a study of 153 trauma patients found the A2/A2 genotype associated with sevenfold increased osteomyelitis risk (OR=7, p<0.001), particularly for Staphylococcus aureus infections — likely reflecting inadequate IL-1Ra-mediated control of IL-1β at the bone-infection interface.

The picture for rheumatoid arthritis is more complex. A meta-analysis of 15 case-control studies found no significant overall association (A2/A2 OR=0.96, p=0.77), though a Mexican case-control study of 657 participants found A1/A2 heterozygotes at modestly elevated RA risk (OR=1.45, p=0.03) with A2/A2 homozygotes showing higher disease activity. Population heterogeneity in LD structure may explain these inconsistencies.

Practical Actions

The actionable implications concentrate on two areas where the evidence is strongest: H. pylori-related gastric disease and periodontal inflammation. For A2 carriers, especially A2/A2 homozygotes, the IL-1β:IL-1Ra imbalance creates a tissue environment where inflammatory damage at mucosal surfaces is harder to resolve. Catching H. pylori infection early and treating it decisively is more important for A2 carriers than for the general population. In the mouth, the severely elevated periodontitis risk for A2 carriers (OR=4+ for severe disease) makes professional dental assessment essential — this is one of the largest genetic effect sizes documented for periodontitis susceptibility.

Interactions

The IL1RN VNTR does not act in isolation — it is part of the IL-1 gene cluster on chromosome 2q14.1 alongside IL-1α (IL1A) and IL-1β (IL1B). The functionally critical pairing is between IL1RN rs2234663 and IL-1B rs1143634 (+3954 C>T) or rs16944 (-511 C>T). When a carrier has both increased IL-1β production (IL1B risk alleles) AND reduced effective IL-1Ra response (IL1RN A2), the IL-1β:IL-1Ra ratio is shifted at both ends simultaneously. This synergy has been documented for gastric cancer, chronic periodontitis, and COPD — with combined genotype odds ratios substantially exceeding those of either variant alone. These combinations represent strong candidates for compound actions in carriers who have been typed at both loci.

TMPRSS6¹¹ TMPRSS6
Transmembrane serine protease 6, also called matriptase-2 — a type II transmembrane serine protease expressed predominantly in the liver, whose key function is to cleave hemojuvelin from hepatocyte surfaces and thereby suppress hepcidin production is the body's primary brake on the iron-regulatory hormone hepcidin²² hepcidin
A 25-amino-acid peptide produced by the liver that controls iron homeostasis by targeting ferroportin, the sole iron export channel on gut enterocytes and macrophages, for degradation. Common TMPRSS6 variants consistently rank among the strongest genetic determinants of serum iron, transferrin saturation, and hemoglobin in genome-wide association studies across diverse populations.

rs2235321 sits in exon 15 of TMPRSS6 at chromosome 22q12.3. The G-to-A change on the plus strand corresponds to a synonymous substitution in the coding sequence — both codons encode tyrosine at position 730 (TAC→TAT, p.Tyr730=). Because the amino acid is unchanged, rs2235321 is not itself the functional variant. Instead, it acts as a haplotype tag³³ haplotype tag
A variant in linkage disequilibrium with one or more nearby functional variants; its alleles reliably predict which haplotype a chromosome belongs to even though the tag variant itself may have no direct functional effect, marking a haplotype that carries altered TMPRSS6 regulatory or splicing activity at a nearby position. The downstream consequence — measured directly in human studies — is a difference in circulating hepcidin levels between GG and AA homozygotes.

The Mechanism

Because rs2235321 is synonymous at the protein level, its association with hepcidin must be mediated through linkage with a nearby functional variant — one that influences TMPRSS6 expression level, mRNA splicing efficiency, or a second coding position in partial LD. Whatever the functional driver, the biological consequence fits the established TMPRSS6–hepcidin–iron axis: the G allele tags reduced effective matriptase-2 activity, leaving more hemojuvelin⁴⁴ hemojuvelin
A GPI-anchored co-receptor that amplifies BMP/SMAD signaling in hepatocytes, driving hepcidin transcription when intact on the cell surface; matriptase-2 cleaves it to dampen this pathway intact on hepatocyte surfaces. More intact hemojuvelin amplifies the BMP/SMAD signaling pathway⁵⁵ BMP/SMAD signaling pathway
Bone morphogenetic protein receptor / SMAD transcription factor cascade that is the primary positive regulator of hepcidin gene expression in the liver, driving hepcidin up. Higher hepcidin degrades ferroportin on duodenal enterocytes and recycling macrophages, tightening the outflow of iron into the bloodstream.

The A allele, by contrast, tags a haplotype with relatively higher matriptase-2 activity: more hemojuvelin is cleaved, BMP/SMAD signaling is damped, hepcidin production falls, and iron absorption and recycling improve.

The Evidence

Two complementary studies from the same Gambian research group provide the primary evidence for rs2235321's association with hepcidin.

A recall-by-genotype study⁶⁶ recall-by-genotype study
Jallow MW et al. Common Variants in the TMPRSS6 Gene Alter Hepcidin but not Plasma Iron in Response to Oral Iron in Healthy Gambian Adults. Curr Dev Nutr, 2021 recruited 80 healthy adults stratified by TMPRSS6 genotype and administered a single oral dose of ferrous sulfate (130 mg elemental iron). At baseline, GG homozygotes had significantly higher plasma hepcidin than AA homozygotes (9.50 vs 6.60 ng/mL, P = 0.035) — a 44% difference. The G allele showed a clear additive dose-response, with heterozygotes (AG) intermediate between the two homozygote groups.

A larger cross-sectional analysis⁷⁷ larger cross-sectional analysis
Jallow MW et al. Association of common TMPRSS6 and TF gene variants with hepcidin and iron status in healthy rural Gambians. Sci Rep, 2021 in 1,316 healthy Gambians confirmed the association: rs2235321 significantly affected plasma hepcidin concentrations (AA genotype having lower hepcidin; F = 3.7, P = 0.014). Notably, rs2235321 was the only TMPRSS6 variant in that cohort that independently affected hepcidin — neither rs855791 nor other genotyped TMPRSS6 variants reached significance for hepcidin in this African population, suggesting rs2235321 tags a distinct functional element at the TMPRSS6 locus that is informative beyond the primary Ala736Val coding variant.

In a prospective pregnancy cohort⁸⁸ prospective pregnancy cohort
Hayashi I et al. Association of a pro-inflammatory diet and gestational diabetes mellitus with maternal anemia and hemoglobin levels during pregnancy. Nutr Res, 2023, rs2235321 was associated with hemoglobin levels during the third trimester — a period of high iron demand when even modest absorption inefficiencies become clinically relevant.

ClinVar classifies this variant as benign, reflecting that it does not cause Mendelian disease on its own. The iron-status effects are modest, population-wide, and relevant primarily under conditions of increased iron demand rather than in nutritionally adequate populations. The evidence level is rated moderate: the hepcidin association is replicated across two independent analyses in African adults, with pregnancy-cohort replication in a separate population, but large-scale multi-ethnic conditional GWAS data specifically for hepcidin remain limited.

Practical Actions

The practical relevance of rs2235321 scales with iron demand. Under conditions of adequate dietary iron and no additional stressors, even GG homozygotes typically maintain normal hemoglobin. The gap between GG and AA becomes meaningful when iron demand is chronically elevated: heavy menstrual cycles, pregnancy, regular blood donation, endurance athletics, or vegetarian and vegan diets where only non-heme iron is available.

For GG individuals in these situations, the actionable steps mirror those for other TMPRSS6 iron-reducing variants: maximize dietary iron absorption through meal composition (vitamin C pairing, avoiding inhibitors), monitor serum ferritin periodically, and choose iron bisglycinate over ferrous sulfate if supplementation is needed. AA individuals can use their genetically lower hepcidin as reassurance that iron deficiency is less likely — though high-demand states can deplete anyone's stores.

Interactions

rs2235321 belongs to the same TMPRSS6 locus as the primary coding variant rs855791⁹⁹ rs855791
Ala736Val missense variant; the strongest common genetic determinant of iron status, with the A allele reducing matriptase-2 enzyme activity directly, the intronic variant rs2413450¹⁰¹⁰ rs2413450
TMPRSS6 intronic tag variant independently associated with MCV, MCH, and hemoglobin in GWAS of over 700,000 individuals, and the upstream regulatory variants rs228918 and rs228921. These variants are partially correlated through linkage disequilibrium¹¹¹¹ linkage disequilibrium
Non-random co-inheritance of alleles at nearby loci because they sit close together on the chromosome and are rarely separated by recombination in the population but capture partially distinct functional signals. In the Jallow 2021 Gambian cohort, rs2235321 showed independent hepcidin effects even when rs855791 did not — suggesting it tags a haplotype element active in African ancestry populations where the LD structure around rs855791 differs from European populations.

Carriers of multiple TMPRSS6 risk alleles across these variants may have a compounded hepcidin-elevating effect. In practice, ferritin monitoring resolves the question of whether the combined genetic architecture translates into meaningful iron depletion for a specific individual.

The luteinizing hormone/choriogonadotropin receptor (LHCGR) sits on the surface of ovarian theca cells, testicular Leydig cells, and luteinized granulosa cells, where it receives LH and hCG signals that drive ovulation, progesterone production, and testosterone synthesis. The N312S variant — a single amino acid change at position 312 from asparagine (N) to serine (S) — sits in exon 10 near a glycosylation site in the extracellular domain¹¹ near a glycosylation site in the extracellular domain
The asparagine at position 312 is a potential N-linked glycosylation sequon; replacing it with serine eliminates this site. This change alters receptor sensitivity to LH signaling, with measurable consequences for PCOS risk, ovarian reserve longevity, and IVF treatment response.

The Mechanism

LHCGR is a G protein-coupled receptor. When LH binds, the receptor activates Gs proteins, stimulating adenylyl cyclase to produce cAMP, which drives steroidogenesis and ovulation. The N312S variant changes a potential N-linked glycosylation site in the receptor's ectodomain. Asparagine (N) at position 312 can be glycosylated, while serine (S) cannot. In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity²² In vitro studies of granulosa cells show that women homozygous for asparagine at both LHCGR 312 and FSHR 680 display lower cAMP activity
Reduced receptor signaling when both gonadotropin receptors carry the asparagine variant compared to serine homozygotes. The asparagine variant appears to create a receptor that is more sensitive to LH — requiring less LH to achieve the same downstream effect — which sounds advantageous but can dysregulate the tightly calibrated LH-FSH balance that governs normal follicular development.

The Evidence

PCOS risk. A 2012 case-control study in 198 PCOS and 187 control Sardinian women³³ A 2012 case-control study in 198 PCOS and 187 control Sardinian women
Capalbo et al. Clinical Endocrinology 2012 found that carrying at least one N allele (T on plus strand) increased PCOS risk 2-fold (OR 2.04, 95% CI 1.32–3.14, P=0.001), with NN homozygotes at 2.7-fold risk (OR 2.73, 95% CI 1.25–5.95, P=0.01). A 2015 Indian study⁴⁴ A 2015 Indian study
Thathapudi et al. Genetic Testing and Molecular Biomarkers found the SS genotype (GG on coding strand) associated with higher PCOS risk in their population (OR 3.36), elevated BMI, and higher LH/FSH ratios — though the direction of the risk allele differed from the Sardinian study, highlighting population heterogeneity. A recent meta-analysis of 10 studies (1,431 PCOS cases, 1,317 controls) found no significant overall association, suggesting the effect may be population-specific rather than universal.

Ovarian aging. A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency⁵⁵ A 2025 multicenter study of 1,240 Chinese women with diminished ovarian reserve or primary ovarian insufficiency
Ma et al. Reproductive Biology and Endocrinology 2025 versus 72,846 controls found the TT genotype (NN) at 3.7-fold increased risk of POI (OR 3.73, 95% CI 2.09–6.67, P<0.001). Critically, TT carriers were diagnosed with POI approximately 7 years earlier (25.5 ± 6.4 years) than CC carriers (32.0 ± 5.1 years). The CT genotype (NS) also showed elevated DOR risk (OR 1.47, 95% CI 1.27–1.69). This large-scale finding positions LHCGR N312S as a potential biomarker for accelerated ovarian aging.

IVF outcomes. A prospective study of 617 IVF patients⁶⁶ A prospective study of 617 IVF patients
Lindgren et al. Human Reproduction 2016 found that LHCGR S312 carriers (C allele) had higher pregnancy rates (OR 1.61, P=0.008), and women homozygous for serine at both LHCGR and FSHR achieved dramatically higher pregnancy rates (OR 14.4, P=0.016). The follow-up study of 665 women⁷⁷ The follow-up study of 665 women
Lindgren et al. Journal of Assisted Reproduction and Genetics 2019 confirmed that women with 4 serine alleles across both receptors had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other genotypes (adjusted HR 1.89, P=0.049). Genotype-guided LH supplementation⁸⁸ Genotype-guided LH supplementation
Ramaraju et al. Frontiers in Endocrinology 2021 in 193 women showed improved pregnancy rates when LH dosing was matched to N312S genotype (P=0.049).

However, the evidence is not unanimous. A 2022 study of 1,183 patients⁹⁹ A 2022 study of 1,183 patients
Pirtea et al. Fertility and Sterility found no significant association between FSHR/LHCGR polymorphisms and oocyte yield, blastocyst rate, implantation, or live birth, concluding these variants "should not be considered reproductive predictors." This discrepancy may reflect differences in stimulation protocols, population composition, or the statistical power needed to detect interaction effects.

Practical Implications

The clinical utility of LHCGR N312S genotyping is strongest in two contexts: assessing PCOS risk and personalizing IVF protocols.

For women with TT (NN) genotype, the enhanced LH receptor sensitivity may contribute to the LH-driven androgen excess that characterizes PCOS. The 2025 Chinese study's finding of accelerated ovarian aging in TT carriers suggests this genotype warrants proactive ovarian reserve monitoring, particularly for women planning to delay childbearing.

For IVF, the interaction between LHCGR and FSHR genotypes defines a pharmacogenetic profile. Women with CC at both rs2293275 and rs6166 (SS at both receptors) appear to have an optimally responsive gonadal axis for ART, while TT carriers at LHCGR may benefit from adjusted LH supplementation protocols. The genotype-guided approach — withholding exogenous LH from NN carriers (whose receptors are already highly sensitive) and providing full-dose LH to SS carriers — showed promising results in the Ramaraju 2021 trial.

For men, LHCGR mediates LH signaling to Leydig cells for testosterone production. While specific rs2293275 data in male fertility is limited, the receptor's role in spermatogenesis makes this variant relevant to male reproductive assessment.

Interactions

FSHR rs6166 (N680S): The strongest documented interaction is with the FSH receptor N680S variant. Women homozygous for serine at both LHCGR N312S (CC genotype) and FSHR N680S (GG genotype) — the "4S" phenotype — had a 62% cumulative live birth rate across three IVF cycles versus 43–47% for other combined genotypes (adjusted HR 1.89, P=0.049). In vitro, granulosa cells from women homozygous for asparagine at both receptors showed lower cAMP activity, suggesting a combined receptor sensitivity profile. This interaction defines a pharmacogenetic subgroup: 4S women appear to respond particularly well to standard IVF protocols, while 4N women (TT at rs2293275 + AA at rs6166) may represent a distinct poor-response phenotype requiring protocol modification.

Compound implication for LHCGR TT + FSHR AA: Women carrying TT at rs2293275 and AA at rs6166 (4N phenotype) may have a combined receptor sensitivity profile that paradoxically impairs IVF response despite individually heightened receptor sensitivity. These women may benefit from modified stimulation protocols with carefully titrated gonadotropin dosing and extended monitoring. Conversely, the 4S phenotype (CC at rs2293275 + GG at rs6166) may represent the optimal pharmacogenetic profile for standard ART protocols.

Most people have never heard of TYK2, yet this kinase sits at the crossroads of three of the most clinically important cytokine pathways in autoimmune disease. TYK2¹¹ TYK2
Tyrosine kinase 2, a member of the JAK (Janus kinase) family that couples cytokine receptor signals to downstream transcription factor activation transduces signals from IL-12, IL-23, and type I interferon receptors — the same pathways targeted by modern immunology drugs and disrupted in lupus, rheumatoid arthritis, psoriasis, and type 1 diabetes. The rs2304256 (V362F) variant is a common allele that subtly shifts how TYK2 is expressed and processed, with measurable downstream protection across this disease spectrum.

Unlike the better-known TYK2 p.Pro1104Ala variant (rs34536443), which directly impairs kinase domain activity, V362F operates through a different mechanism: it promotes the inclusion of exon 8 in the mature TYK2 transcript, which is required for TYK2 to bind its cognate cytokine receptors. Carriers of the A allele show mildly enhanced TYK2 expression in whole blood — an effect that appears, paradoxically, to dampen rather than amplify net autoimmune signaling output, possibly through enhanced regulatory signaling or feedback inhibition.

The Mechanism

rs2304256 maps to exon 8 of TYK2 at chromosome 19p13.2 (GRCh38 position 10,364,976). The variant encodes a valine-to-phenylalanine substitution at residue 362 (p.Val362Phe) in the FERM (four-point-one, ezrin, radixin, moesin) domain of TYK2, which mediates receptor binding and is essential for correct cytokine receptor coupling.

Li et al. (2020)²² Li et al. (2020) demonstrated that rs2304256 — together with the intronic variant rs12720270 in intron 7 — promotes inclusion of exon 8 in TYK2 mRNA. Since exon 8 encodes part of the FERM domain required for receptor binding, its inclusion affects receptor affinity and downstream signal calibration. The A allele at rs2304256 also acts as a cis-eQTL³³ cis-eQTL
A cis-eQTL (expression quantitative trait locus) is a genetic variant that influences the expression level of a nearby gene; "cis" means the gene affected is on the same chromosome for TYK2 in whole blood, mildly increasing TYK2 transcript levels.

This mechanism is distinct from — and independent of — the pseudokinase domain variant rs34536443 (p.Pro1104Ala), which directly impairs kinase regulatory activity. The two variants affect different functional domains through different molecular mechanisms and are in weak linkage disequilibrium, meaning individuals can carry either, both, or neither protective allele.

The Evidence

The protective effects of rs2304256 are among the most replicated in TYK2 genetics. A meta-analysis by Tao et al. (2011)⁴⁴ meta-analysis by Tao et al. (2011) pooling 11 studies with 21,497 cases and 22,647 controls found the A allele confers OR 0.78 (95% CI 0.70–0.87, P<0.0001) for autoimmune and inflammatory diseases. The protection follows an additive dose-response: CA heterozygotes show OR 0.70 (P<0.0001), while AA homozygotes show OR 0.64 (P=0.003) compared to CC.

For autoimmune rheumatic diseases specifically, Lee and Bae (2016)⁵⁵ Lee and Bae (2016) analyzed 12 studies (16,335 patients / 30,065 controls) and found the A allele OR 0.885 overall, with a stronger protective effect in Caucasians (OR 0.822). For SLE in Caucasians specifically, the protection reaches OR 0.737 — a substantial 26% odds reduction that is statistically robust but absent in Asian populations, where A allele frequency is considerably higher and the genetic architecture of autoimmune risk differs.

The most striking single-disease evidence comes from type 1 diabetes. Pellenz et al. (2021)⁶⁶ Pellenz et al. (2021) demonstrated that in a Brazilian cohort, AA homozygotes had OR 0.48 (95% CI 0.29–0.81) for T1D under a recessive model — essentially halved risk — with equivalent protection under the additive model (OR 0.47, P<0.0001). The mechanism likely involves TYK2's role in interferon-driven pancreatic beta-cell apoptosis during insulitis, the early inflammatory phase preceding T1D.

A comprehensive 2021 systematic review and meta-analysis⁷⁷ 2021 systematic review and meta-analysis of 34 studies across eight autoimmune conditions confirmed rs2304256's protective association as one of the most consistently observed in TYK2 genetics, spanning MS, SLE, RA, Crohn's disease, ulcerative colitis, psoriasis, RA, and T1D.

Practical Implications

The A allele at rs2304256 is common — about 28% frequency in Europeans and 46% in East Asians — making AA homozygosity a real possibility (~8% of Europeans, ~21% of East Asians). Unlike the ultra-rare P1104A allele at rs34536443, this variant's protection is accessible to a substantial portion of the general population.

For CA and AA carriers, this result is most relevant in three contexts: (1) when being evaluated for autoimmune conditions, where it provides some baseline reassurance and may contextualize immune workup thresholds; (2) when any JAK or TYK2 inhibitor therapy is being considered, since baseline TYK2 signaling differs from the population norm; and (3) when considering family risk counseling for autoimmune diseases.

Pharmacologically, deucravacitinib (Sotyktu), the FDA-approved TYK2 pseudokinase inhibitor, operates on a different domain than V362F affects — but both influence TYK2-mediated signaling. Carriers of the A allele at rs2304256 may have subtly different baseline responses to TYK2 inhibitor therapy compared to CC homozygotes, though this has not been formally studied.

Interactions

rs2304256 is one of at least four independent protective signals in the TYK2 gene. The most studied is rs34536443 (p.Pro1104Ala), which affects the pseudokinase domain and is notably rarer (~4% in Europeans). The two variants operate through independent mechanisms (splicing/expression vs. kinase domain allostery) and are additive — carriers of the A allele at rs2304256 who also carry the C allele at rs34536443 have two distinct layers of TYK2 attenuation.

The intronic variant rs12720270 is in linkage disequilibrium with rs2304256 and acts through the same exon 8 splicing mechanism; the two variants were identified together in the same functional study. rs12720356 is a third independent protective TYK2 signal.

Beyond TYK2, the protective effect of rs2304256 acts within the broader autoimmune genetic architecture that includes PTPN22 (rs2476601), CTLA4 (rs3087243), and HLA class II loci — variants that modulate T cell activation thresholds through different mechanisms. Combined protective alleles across these loci likely confer additive reductions in autoimmune disease susceptibility, though formal compound interaction studies are limited.

TMPRSS6¹¹ TMPRSS6
Transmembrane serine protease 6, also called matriptase-2 — a liver-expressed enzyme that negatively regulates iron absorption by cleaving hemojuvelin from the hepatocyte surface, thereby suppressing hepcidin production sits at the centre of the body's iron-sensing machinery. Its most studied variant — Ala736Val (rs855791) — is the single strongest common genetic determinant of iron status. rs2413450 is a second, independent marker at the same locus: an intronic variant located approximately 426 nucleotides downstream of exon 14 in the TMPRSS6 transcript. It does not itself change the protein sequence, but its alleles tag functional variation in TMPRSS6 expression or splicing regulation, and it has been independently replicated in GWAS for red blood cell traits.

The Mechanism

Because rs2413450 is intronic, it does not directly alter the matriptase-2 protein. Instead, it acts as a regulatory tag variant²² regulatory tag variant
A non-coding variant in linkage disequilibrium with nearby functional variants, or one that directly affects intronic splicing enhancer/silencer sequences or gene expression levels. The T allele at rs2413450 is associated with lower matriptase-2 activity, either through altered splicing efficiency or by tagging a haplotype that carries reduced-function regulatory elements. Less active matriptase-2 means less cleavage of hemojuvelin³³ hemojuvelin
A co-receptor of BMP receptors on hepatocyte surfaces that amplifies BMP/SMAD signalling and thereby drives hepcidin transcription, which in turn raises hepcidin. Higher hepcidin degrades ferroportin⁴⁴ ferroportin
The only known iron exporter on the basolateral surface of duodenal enterocytes and macrophages — hepcidin binding triggers its internalization and degradation, blocking iron release into the bloodstream on gut enterocytes, limiting iron entry into the circulation. The net result is the same as for the coding variant rs855791: smaller red blood cells (lower MCV), less hemoglobin per cell (lower MCH), and modestly reduced hemoglobin concentration.

The Evidence

The association was first reported in the landmark CHARGE Consortium GWAS⁵⁵ CHARGE Consortium GWAS
Ganesh SK et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet, 2009, which studied 24,167 Europeans and confirmed rs2413450 associated with MCV (P = 3 × 10⁻⁴¹), MCH (P = 9 × 10⁻³⁴), and hematocrit (P = 2 × 10⁻¹³) — effect sizes comparable to the primary TMPRSS6 missense variant.

A large trans-ethnic meta-analysis Chen et al.⁶⁶ Chen et al.
Chen MH et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell, 2020 confirmed the T allele reduces MCH by 0.126 standard deviations (P = 5 × 10⁻¹⁶) across European, East Asian, African, South Asian, and Latino populations, establishing this as a robust multi-ethnic signal.

In African-ancestry cohorts⁷⁷ African-ancestry cohorts
Gichohi-Wainaina WN et al. Associations between Common Variants in Iron-Related Genes with Haematological Traits in Populations of African Ancestry. PLoS One, 2016, rs2413450 T carriers showed a 0.19 g/dL reduction in hemoglobin (P = 0.02), one of only four TMPRSS6 variants that successfully replicated European GWAS signals in African populations — suggesting the functional variant it tags is ancestrally shared rather than population-specific.

A Turkish case-control study Batar et al.⁸⁸ Batar et al.
Batar B et al. The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia. Gene, 2018 found that rs2413450 was associated with elevated total iron-binding capacity in IDA patients — a marker of iron-starved erythropoiesis — consistent with the GWAS direction.

The evidence level is rated strong: the association has been replicated in multiple independent cohorts spanning diverse ancestries and total sample sizes exceeding 700,000 individuals. Effect sizes are modest (fractions of a standard deviation per allele) but robust.

Practical Implications

Carrying one or two copies of the T allele does not cause iron deficiency on its own. The effect is sub-clinical under conditions of adequate dietary iron. But when iron demand rises — during heavy menstrual cycles, pregnancy, vegetarian or vegan eating, endurance athletics, or blood donation — T carriers have a narrower margin before iron stores drop into deficiency range.

The most actionable step is knowing your ferritin level. Serum ferritin below 30 µg/L indicates depleted stores even when hemoglobin is still within range; below 12 µg/L is overt deficiency. If stores are adequate, standard dietary guidance applies. If stores trend low, dietary strategies to maximize absorption become important: pairing iron-rich foods with vitamin C, avoiding tea and coffee within an hour of iron-containing meals, and choosing iron bisglycinate⁹⁹ iron bisglycinate
A chelated form absorbed via peptide transporters, partially bypassing hepcidin-controlled ferroportin, and better tolerated than ferrous sulfate in sensitive individuals over ferrous sulfate if supplementing.

Interactions

This variant operates through the same hepcidin pathway as the primary TMPRSS6 missense variant rs855791. Carrying the T allele at rs2413450 in addition to the A allele at rs855791 may compound the iron-reducing effect, since both tag haplotypes with reduced matriptase-2 function — though the two variants are not in perfect linkage disequilibrium and capture partially overlapping and partially independent variance.

Interaction with HFE variants (rs1800562 C282Y, rs1799945 H63D) is the most clinically relevant context: HFE loss-of-function raises hepcidin sensitivity and causes iron overload, while TMPRSS6 T alleles raise hepcidin and limit absorption. In someone with borderline HFE heterozygosity, TMPRSS6 T alleles may actually attenuate iron accumulation. In someone with purely nutritional iron deficiency risk, no HFE context is needed — the TMPRSS6 effect stands alone.

Every cell in your body constantly displays a sample of its internal protein inventory on its surface, using molecules of the MHC class I system¹¹ MHC class I system
Major Histocompatibility Complex class I proteins (HLA-A, HLA-B, HLA-C) that present 8-10 amino acid peptides to patrolling CD8+ T cells for immune surveillance as display platforms. Before a peptide can be loaded, it must first be trimmed to the right length inside the endoplasmic reticulum²² endoplasmic reticulum
the cellular compartment where protein folding and quality control occur, and where peptides destined for HLA class I presentation are processed. ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) is the enzyme that performs this trimming — clipping amino acids from the N-terminus of longer precursor peptides until an optimal 8-10-mer is generated. The rs26653 variant subtly modifies the ERAP1 protein at position 127, and the resulting shift in trimming behavior has documented consequences for risk of psoriasis and ankylosing spondylitis.

The Mechanism

rs26653 is a missense variant (c.380G>C in coding notation) that substitutes a proline for an arginine at amino acid position 127 of ERAP1 (p.Arg127Pro). Position 127 sits in an N-terminal regulatory domain of the enzyme, outside the catalytic site and peptide-binding pocket. Structural and biochemical analyses suggest that the proline substitution reduces conformational flexibility at this position³³ proline substitution reduces conformational flexibility at this position
proline is a cyclic amino acid that restricts the backbone dihedral angles available to a peptide chain, potentially affecting interdomain motion and allosteric transitions in the enzyme, consistent with the observation that ERAP1 allotypes carrying Pro127 tend to have modestly lower catalytic activity overall, though no single in vitro study has isolated the effect of this variant alone.

The clinical significance of rs26653 arises not from a dramatic loss of enzymatic activity, but from subtle shifts in the peptide repertoire ultimately loaded onto MHC class I molecules. In individuals who carry the immune-sensitizing HLA alleles HLA-C*06:02 (associated with psoriasis) or HLA-B27 (associated with ankylosing spondylitis), even small changes in which peptides are generated and in what abundance can tip the balance toward aberrant self-recognition. The ERAP1 locus has now been shown to interact [epistatically | a situation where the clinical effect of one gene depends on the genotype at a second, separate locus] with both HLA-C*06:02 and HLA-B27, meaning that rs26653's disease risk operates primarily through — and is amplified by — specific HLA backgrounds.

The Evidence

Psoriasis: Age-stratified signal. A large Swedish psoriasis cohort study first highlighted rs26653 as an independently significant ERAP1 variant, distinct from the previously characterized rs27524 and rs30187. This study⁴⁴ This study
Lysell et al. Genetic association with ERAP1 in psoriasis is confined to disease onset after puberty and not dependent on HLA-C*06. J Invest Dermatol, 2013 found that rs26653 was associated with psoriasis overall (OR=1.31, 95% CI 1.16–1.48), but the association was dramatically concentrated in individuals whose psoriasis appeared between ages 10 and 20 (OR=1.59, 95% CI 1.28–1.98, P=0.00008). Prepubertal onset (ages 0–9) lacked association, as did late-onset disease (>40 years). Importantly, the association was not modulated by HLA-C*06:02 status — making rs26653's age-specific effect mechanistically distinct from rs27524's HLA-C*06:02-dependent effect.

A Chinese case-control study found a similar signal for psoriasis vulgaris: Pro127 homozygotes had nearly double the risk of psoriasis⁵⁵ Pro127 homozygotes had nearly double the risk of psoriasis
OR=1.96 for CC vs GG; C allele OR=1.40, P=0.042; stronger in early-onset subgroup (OR=2.08, P=0.036).

Ankylosing spondylitis: HLA-B27-conditioned epistasis. The original landmark discovery of ERAP1's role in AS came from a genome-wide study demonstrating that ERAP1 variants affect AS risk exclusively in HLA-B27-positive individuals. Evans et al.⁶⁶ Evans et al.
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet, 2011 reported a combined interaction P-value of 7.3×10⁻⁶, with no detectable ERAP1 effect in HLA-B27-negative individuals. A Turkish population study found that rs26653 specifically was associated with AS susceptibility (OR=1.609, 95% CI 1.163–2.226, p=0.004), with a population-attributable risk of 23.4%, though notably no stratification by HLA-B27 status revealed a significant interaction in that smaller cohort.

A meta-analysis pooling 24,271 AS patients and 42,666 controls found that rs26653's AS association was population-specific: statistically significant in Caucasian populations, not significant in Asians, which contributed to the overall pooled OR (1.15, 95% CI 0.94–1.42) crossing the null.

Functional context. In biochemical studies examining ERAP1 allotypes, Pro127-containing allotypes show modestly lower rates of substrate processing compared to Arg127-containing allotypes in some contexts. Studies ranking ERAP1 polymorphisms' contribution to HLA-B27 peptidome shaping⁷⁷ Studies ranking ERAP1 polymorphisms' contribution to HLA-B27 peptidome shaping
Kochan et al., PMC6030728 note that prior in vitro work found no isolated effect of R127P on trimming — the functional consequences of rs26653 may be context-dependent, emerging primarily within specific allotype combinations or HLA environments rather than in isolation.

Practical Implications

Carrying one or two copies of the G allele (Pro127) means your ERAP1 enzyme trimming landscape is subtly shifted. The most clinically relevant implication depends on your HLA background:

For psoriasis risk, the association is strongest if your skin condition appeared or appears in adolescence (ages 10–20) — rs26653 may be a contributing factor even in the absence of HLA-C*06:02. For ankylosing spondylitis, the ERAP1 locus primarily matters if you are HLA-B27 positive. If you carry both HLA-B27 and ERAP1 risk variants, your AS risk is substantially higher than either factor alone.

Both conditions are chronic and manageable with early recognition. For psoriasis, prompt treatment prevents skin thickening and joint involvement. For ankylosing spondylitis — inflammatory back pain that is classically worse in the morning, improves with activity, and comes on before age 45 — early diagnosis and treatment with NSAIDs or biologics dramatically reduces the risk of permanent spinal fusion.

Interactions

rs26653 × HLA-C*06:02 (rs12191877): Partially independent in psoriasis. Unlike rs27524, which shows strict dependence on HLA-C*06:02 for its psoriasis effect, rs26653's age-stratified psoriasis signal is not abolished in HLA-C*06:02-negative individuals. This suggests rs26653 may influence a broader set of peptide/HLA interactions, or that adolescent-onset psoriasis involves different immunological substrates than adult-onset plaque psoriasis.

rs26653 × HLA-B27: Epistasis in ankylosing spondylitis. The ERAP1 locus broadly interacts with HLA-B27 in AS pathogenesis. The mechanism is mechanistic necessity⁸⁸ The mechanism is mechanistic necessity
ERAP1 trims peptides that are then loaded onto HLA-B27; altered trimming changes which self-peptides are presented, potentially generating arthritogenic peptides or increasing free heavy chain formation. Compound risk in HLA-B27-positive individuals carrying multiple ERAP1 risk alleles (including rs26653 + rs30187) is documented.

rs26653 × rs30187 (ERAP1 Lys528Arg): Same-gene haplotype effects. rs26653 and rs30187 are both missense variants in ERAP1 and travel together on haplotypes. The protective haplotype (rs30187/rs26618/rs26653 with alleles C-T-G, where G = Arg127 coding-strand notation) is associated with reduced AS risk (OR=0.77). This means the combination of Arg127 (rs26653) and Lys528 (rs30187) residues in the same ERAP1 protein defines a high-risk allotype, while Arg528 (rs30187 protective variant) tends to reduce trimming activity regardless of rs26653 status.

The interaction between rs26653 and rs30187 is a strong candidate for a compound action: individuals carrying risk alleles at both sites have a different ERAP1 allotype with distinct immunopeptidome characteristics compared to those with mixed or protective allotypes at both sites.

Von Willebrand factor (VWF) performs two simultaneous jobs inside a damaged blood vessel: it rolls out like a molecular carpet to which platelets can stick, and it ferries coagulation Factor VIII¹¹ coagulation Factor VIII
Factor VIII is the plasma protein deficient in haemophilia A; VWF acts as its stabilizing carrier, protecting it from premature destruction in the bloodstream to the site of injury. Both jobs require VWF's three functional domains — A1 (platelet GpIb binding), A3 (collagen binding), and D (Factor VIII binding) — to work in concert. The rs267607353 variant swaps serine for alanine at residue 1783 of the A3 domain, dismantling just one of these functions: the ability to grip collagen in the vessel wall.

The result is a bleeding disorder that standard coagulation panels routinely miss. Multimers look normal. VWF antigen is normal. The ristocetin cofactor assay (VWF:RCo, which tests platelet-binding) is normal. Only a dedicated collagen-binding assay (VWF:CB) reveals the defect — and most haematology labs do not run it unless specifically requested. This is von Willebrand disease type 2M²² von Willebrand disease type 2M
The "M" stands for "multimer-independent," meaning the collagen-binding defect is not due to loss of high-molecular-weight multimers as in type 2A disease, also described as type 2CB (collagen-binding subtype). Carriers can bleed significantly from dental extractions, surgeries, and childbirth while appearing fully normal on routine haematological workup.

The Mechanism

The VWF A3 domain folds into a von Willebrand A fold³³ von Willebrand A fold
A barrel-like beta-sheet structure common to VWF, integrins, and complement proteins; its surface groove coordinates the collagen interaction that positions a specific surface groove to engage collagen types I and III in the extracellular matrix. Serine 1783 sits within this groove. In the wild-type protein, serine's hydroxyl group contributes a hydrogen bond that maintains the precise geometry of the collagen-contact interface. Substituting alanine — which lacks that hydroxyl side chain — disrupts this geometry without altering the overall multimer structure or Factor VIII binding.

Recombinant S1783A VWF expressed and studied by Riddell et al. showed "a pronounced binding defect to both type I and type III collagen" relative to wild-type, while multimer gels were "indistinguishable from wild-type." This mechanistic specificity — collagen binding lost, everything else preserved — is what makes this variant diagnostically elusive and clinically significant.

The Evidence

The key characterization study is Riddell et al., Blood 2009⁴⁴ Riddell et al., Blood 2009
Riddell AF, Gomez K, Millar CM et al. Blood 114(16):3489-96; doi:10.1182/blood-2008-10-184317 — identified S1783A and W1745C as novel A3-domain mutations in three families with bleeding symptoms and normal routine VWD assays; proposed reclassification of isolated collagen-binding defects as a distinct disease subtype. S1783A was identified as a heterozygous variant in a mother-son pair with bleeding symptoms — normal VWF antigen, normal VWF:RCo, normal multimers, but abnormal collagen binding to both collagen I and III. The variant segregated with the phenotype, and the S1783A mutation was absent from the reference allele population. ClinVar (variation 31012) lists the pathogenic classification from OMIM (allelic variant 613160.0042) along with a 2023 Variantyx submission noting variable expressivity consistent with incomplete penetrance.

The importance of dedicated collagen-binding assays is established by Favaloro and Mohammed, 2014⁵⁵ Favaloro and Mohammed, 2014
Favaloro EJ, Mohammed S. Thromb Res 135(6):1307-16, 2014 — comparative evaluation of VWF assay platforms across 600 samples; VWF:CB was most discrepant from VWF:RCo precisely in type 2M patients, confirming VWF:CB is irreplaceable for this subtype. Without a VWF:CB assay in the diagnostic workup, type 2M/2CB cases are systematically missed.

Evidence level is assessed as strong: the causal mechanism is characterised at the recombinant-protein level, the variant segregates with disease in affected pedigrees, ClinVar lists a pathogenic submission, and the collagen-binding assay literature supports the diagnostic framework. However, published case numbers are small (one pedigree for S1783A specifically) and the full penetrance spectrum is not yet established from population-level data.

Practical Actions

For carriers, the priority is to make the invisible visible: the bleeding risk is real but will remain undetected unless haematologists are told to request a VWF collagen-binding assay. Carriers undergoing surgery, dental procedures, or childbirth need a haematologist involved in pre-procedural planning. DDAVP (desmopressin) — the first-line treatment for VWD type 1 — releases endogenous VWF stores but is unlikely to be effective for this variant because the released VWF carries the same structural defect. VWF concentrate (Humate-P, Wilate, or similar) is the preferred treatment option when haemostatic cover is needed, since concentrate VWF has normal collagen-binding activity.

Interactions

VWF S1783A acts through loss of collagen contact rather than reduction in VWF quantity or multimer structure. It does not interact with the ABO blood group variant (rs505922) in the same way that quantitative VWD type 1 does — ABO-associated VWF level modulation is relevant to VWF antigen and clearance, not to A3-domain collagen binding. No compound heterozygosity has been published for S1783A with other A3-domain mutations (such as W1745C at rs61749642 or L1733P), though theoretically compound heterozygosity could produce severe type 3-like collagen-binding loss; this has not been documented in clinical series.

Estrogen receptor alpha (ERα), encoded by ESR1 on chromosome 6, is the master mediator of estrogen's effects throughout the reproductive system, skeleton, breast, and cardiovascular tissues. ERα regulates the timing of puberty and menopause, drives follicular development in the ovary, governs endometrial proliferation, and controls hypothalamic feedback that synchronizes the HPG axis. Because so much of female reproductive biology runs through this single receptor, polymorphisms that alter how much ERα is made — or how well it responds to estrogen — can shift the timing and quality of reproductive aging in consequential ways.

rs2747648 sits in the 3′ untranslated region (3′UTR) of ESR1, a stretch of the mRNA transcript that does not encode protein but contains regulatory sequences that govern how efficiently the mRNA is translated and how quickly it is degraded. One key class of 3′UTR regulators is microRNAs¹¹ microRNAs
small non-coding RNA molecules, approximately 22 nucleotides long, that bind to complementary sequences in mRNA 3′UTRs and suppress protein production by blocking translation or triggering mRNA degradation.

The Mechanism

The rs2747648 variant creates or disrupts a binding site for miR-453²² miR-453
microRNA-453, a small regulatory RNA expressed in reproductive and breast tissues that targets ESR1 mRNA for translational repression. Computational analysis confirmed experimentally by Tchatchou et al. 2009³³ Tchatchou et al. 2009
Carcinogenesis — familial breast cancer study of miRNA target site SNPs in cancer-related genes showed that the C allele strengthens miR-453 binding affinity, allowing miR-453 to more effectively suppress ESR1 mRNA translation. The result: lower ERα protein levels in cells carrying the C allele.

The T allele (the allele carried by ~97% of people globally) weakens miR-453 binding. ESR1 mRNA is less efficiently repressed, yielding higher baseline ERα protein levels. This is the population-typical state — most people have TT and average ERα expression at this locus.

Higher ERα levels, while normal, are not neutral for all tissue contexts: in breast epithelium, estrogen receptor signaling drives cellular proliferation, and elevated receptor abundance is a recognized driver of estrogen-dependent breast cancer, particularly in premenopausal women when estrogen levels are highest.

The Evidence

The primary evidence for rs2747648 comes from a familial breast cancer study⁴⁴ familial breast cancer study
Tchatchou et al. Carcinogenesis 2009; analysis of 11 miRNA target site SNPs across a large familial cohort that identified significant association with premenopausal breast cancer risk. Women carrying at least one C allele had OR = 0.60 (95% CI 0.41–0.89, p=0.010) for premenopausal breast cancer compared to TT homozygotes — a 40% reduction in relative risk. The protective effect was even stronger in high-risk familial cases (OR = 0.42, 95% CI 0.25–0.71, p=0.0009).

The fertility and reproductive aging implications of this variant are inferred from the broader ESR1 locus literature. Multiple studies have linked ESR1 polymorphisms to premature ovarian failure (POF) and age at natural menopause. Schuh-Huerta et al. 2012⁵⁵ Schuh-Huerta et al. 2012
Orphanet Journal of Rare Diseases — ESR1 variants associated with both age at natural menopause and premature ovarian failure in independent cohorts showed that nearby ESR1 variants (rs2234693) are significantly associated with both age at menopause and POF risk — consistent with a shared genetic architecture across the ESR1 locus. Cordts et al. 2012⁶⁶ Cordts et al. 2012
Journal of Assisted Reproduction and Genetics — ESR1 PvuII polymorphism associated with POF under a recessive model, p=0.034, in Brazilian women with n=70 POF cases and 73 controls and Yang et al. 2010⁷⁷ Yang et al. 2010
Journal of Women's Health — ESR1 XbaI/PvuII haplotypes modify POF risk; X allele OR 0.6 for idiopathic POF in Korean women further confirm ESR1's role in setting the pace of ovarian aging.

The C allele's impact on ESR1 expression in reproductive tissues has not been directly studied in ovarian or endometrial biopsies for this specific variant. The connection to reproductive function is mechanistically plausible (lower ERα in ovarian follicles and hypothalamic neurons could alter folliculogenesis and GnRH feedback) but is classified as emerging evidence for this specific rsid.

Practical Implications

For the rare individuals (approximately 1 in 20) who carry the C allele (CT or CC), the primary implication is a genetically lower risk of premenopausal breast cancer, driven by reduced ERα abundance. For CT heterozygotes — the dominant non-normal genotype — the effect is partial.

The fertility implications of reduced ERα expression are less well characterized for this specific variant. In animal models, loss of ERα function consistently disrupts follicular maturation, ovulation, and hypothalamic GnRH pulsatility. Whether the modest reduction in ERα expected from one C allele at this regulatory site has any measurable effect on ovarian reserve or menopause timing is not established from direct studies of rs2747648. Monitoring reproductive hormone levels (FSH, AMH, estradiol) provides the most actionable pathway if concerns arise.

Interactions

rs2747648 is in physical proximity to several well-studied ESR1 variants, including rs2234693 (PvuII, intron 1)⁸⁸ rs2234693 (PvuII, intron 1)
ESR1 polymorphism associated with endometrial receptivity, bone density, and POF risk in multiple cohorts, rs9340799 (XbaI, intron 1)⁹⁹ rs9340799 (XbaI, intron 1)
ESR1 variant associated with endometriosis-related infertility and IVF failure, and rs1159327 (intron variant, associated with bone mineral density). Haplotype effects across these variants are likely, since they span the regulatory introns that control ERα tissue-specific expression.

Nuclear factor kappa B (NF-κB) is the master switch of the human inflammatory response. When your immune cells sense a pathogen, tissue damage, or oxidative stress, NF-κB activates dozens of genes that mount the immune defense — but it also activates inhibitory proteins (like IκBα) that eventually turn the response off. The NFKB1 gene encodes the p50 subunit, one of NF-κB's most important components. This variant, located at position -94 in the gene's promoter region¹¹ promoter region
The promoter is the regulatory "on switch" that controls how much gene product is made, is a four-nucleotide insertion (ATTG) whose presence or absence directly controls how much p50 your cells produce. Because p50 is both pro-inflammatory and anti-inflammatory depending on context, this seemingly small genetic difference has ripple effects across cardiovascular disease, autoimmune conditions, and infection susceptibility.

The Mechanism

The -94ins/delATTG polymorphism sits at a key transcription factor binding site in the NFKB1 5′ regulatory region. The foundational functional study²² The foundational functional study
Karban et al. 2004, Human Molecular Genetics — identified this as the first potentially functional NFKB1 polymorphism demonstrated that nuclear proteins from normal human colon tissue and colonic cell lines bind specifically to the insertion allele but not to the deletion allele. Luciferase reporter assays confirmed that constructs carrying the deletion allele generate significantly less NFKB1 promoter activity than those carrying the insertion allele. In other words, the deletion allele produces less NF-κB p50 protein.

This reduction in p50 production creates a paradox: while NF-κB is often framed as a pro-inflammatory transcription factor, the p50 homodimer actually functions as a transcriptional repressor of inflammatory genes³³ transcriptional repressor of inflammatory genes
p50/p50 homodimers competitively displace p50/p65 heterodimers from κB sites, suppressing transcription. Reduced p50 therefore means less negative feedback on inflammatory cytokine production. Laboratory studies using human umbilical vein endothelial cells (HUVECs) from del/del individuals show reduced Bcl-2 expression, lower NF-κB p50 protein, elevated IL-6 production, and increased susceptibility to hydrogen peroxide-induced apoptosis — a picture of both pro-inflammatory dysregulation and impaired endothelial cell survival.

The Evidence

The cardiovascular evidence is the most thoroughly characterized. A 2016 meta-analysis⁴⁴ A 2016 meta-analysis
Chen et al., Genetic Testing and Molecular Biomarkers, pooling 7 case-control studies found that the del/del genotype confers OR 1.26 (95% CI 1.12–1.43) for coronary artery disease (CAD) compared to ins/ins. The ins/del heterozygous genotype showed OR 1.11 (95% CI 1.01–1.21). Effects were present in both Asian (OR 1.47, homozygote model) and Caucasian (OR 1.21) populations.

A 2019 case-control study⁵⁵ A 2019 case-control study
Jin et al., Bioscience Reports — 778 ACS patients vs 1,112 controls in Chinese Han found that the del/del genotype frequency was 18.0% in ACS patients vs 14.1% in controls (P=0.009) and that del/del carriers had 1.33-fold higher ACS risk after multivariate adjustment. Del/del patients also showed significantly more severe coronary stenosis. A concurrent 2020 study⁶⁶ A concurrent 2020 study
Luo et al., Scientific Reports — 359 MI patients vs 1,085 controls found the del allele frequency 41.2% vs 36.4% in controls (P=0.021), and critically, MI patients with del/del had Gensini scores (a measure of coronary stenosis burden) 32–43% higher than other genotypes, along with significantly elevated plasma IL-6 levels and higher rates of multi-vessel disease (P=0.001).

Long-term prognostic data⁷⁷ Long-term prognostic data
Luo et al. 2022, BMC Cardiovascular Disorders — 257 high-risk CVD patients followed for 30 months showed MACE incidence of 32.6% in del/del vs 15.9–16.5% in II and ID carriers, with del/del carriers having approximately 2.3 times the relative risk for major adverse events after controlling for traditional cardiovascular risk factors.

Beyond cardiovascular disease, the polymorphism has been examined in autoimmune contexts. A study of rheumatoid arthritis⁸⁸ A study of rheumatoid arthritis
Elkhawaga et al. 2021, Clinical Rheumatology — 196 Egyptian RA patients found that the del allele was associated with higher IL-6 levels in a dose-dependent manner: del/del carriers had 41.4 ± 16.2 pg/mL, compared to 19.1 ± 12.4 pg/mL for ins/del and 11.4 ± 4.2 pg/mL for ins/ins. Erosive arthritis was associated with combined del genotype carriers (OR 1.86). The original genetic association study⁹⁹ original genetic association study
Karban et al. 2004, the foundational paper identified an association with ulcerative colitis in North American cohorts, positioning this variant as relevant across multiple inflammatory disease domains.

Practical Actions

The del/del genotype creates a substrate of elevated baseline inflammatory signaling through impaired NF-κB p50-mediated feedback suppression. The actionable strategy is to monitor cardiovascular biomarkers proactively and use dietary and targeted supplementation approaches that modulate the NF-κB and cytokine pathways this variant directly affects.

Tracking circulating IL-6 and high-sensitivity CRP directly tests the downstream consequence of this variant — elevated inflammatory cytokine production. Del/del carriers consistently show higher IL-6 in multiple studies across different disease contexts. Identifying individual elevation allows for more targeted intervention and serves as a gauge for whether dietary and supplement strategies are working.

Omega-3 fatty acids (EPA and DHA) downregulate NF-κB activation and reduce IL-6 and other downstream cytokines through lipid mediator pathways (resolvins, protectins) that directly intersect with the NF-κB signaling axis this variant impairs. Specific omega-3 supplementation at 2–3 g EPA+DHA daily has documented effects on IL-6 reduction in inflammatory disease contexts.

Interactions

The most clinically relevant interaction is with other NF-κB pathway modulators. NFKBIA (IκBα) variants — particularly in the 3′UTR — interact with NFKB1 to modulate overall NF-κB tone; rs28362491 del/del combined with NFKBIA risk genotypes may create compounded dysregulation. CARD15/NOD2 mutations in Crohn's disease have been examined alongside this variant without definitive interaction effects in European populations, though the NF-κB pathway mechanistically connects them.

Within cardiovascular risk, del/del carriers who also carry NOS3 (eNOS) variants reducing nitric oxide production face a dual hit: impaired endothelial NF-κB signaling AND reduced vasodilation capacity. The eNOS reduction seen in del/del HUVEC cells in laboratory studies (Luo 2017) suggests particular relevance for variants in rs1799983 (NOS3 Glu298Asp).

The HLA-DPA1 gene¹¹ HLA-DPA1 gene
Human Leukocyte Antigen class II, DP Alpha 1 — encodes the alpha chain of the HLA-DP heterodimer, a surface receptor on antigen-presenting cells that displays peptide fragments to CD4+ T helper cells, initiating adaptive immune responses against pathogens sits at the centre of how your immune system recognises and clears hepatitis B virus (HBV). The rs3077 variant sits in the 3′ untranslated region of this gene — not altering the protein itself, but controlling how much of it gets made. The G allele at this position (equivalent to the C allele on the coding strand in many papers, because HLA-DPA1 is transcribed from the minus strand) silences HLA-DPA1 production in the liver, leaving the immune system less equipped to present HBV antigens and mount a clearing T-cell response.

The Mechanism

HLA-DP molecules are class II major histocompatibility complex²² major histocompatibility complex
MHC — the genomic region on chromosome 6p21 encoding cell-surface proteins that present peptide antigens to immune cells; essential for self/non-self discrimination and adaptive immunity proteins expressed on antigen-presenting cells — dendritic cells, B cells, macrophages, and Kupffer cells in the liver. They display short viral peptides to CD4+ T helper cells, which in turn coordinate antibody production by B cells and activation of CD8+ cytotoxic T cells that kill virus-infected hepatocytes. The rs3077 variant is the single strongest expression quantitative trait locus³³ expression quantitative trait locus
eQTL — a genetic variant that controls the quantity of mRNA produced from a nearby gene; the rs3077 signal for HLA-DPA1 mRNA reached p=10⁻⁴⁸ in a genome-wide scan of liver tissue for HLA-DPA1 mRNA in human liver. Carrying the G allele means liver cells produce less HLA-DPA1 protein — meaning fewer HBV peptides are displayed, CD4+ T-cell help is blunted, and the virus is more likely to establish chronic infection rather than being cleared.

The Evidence

The association between rs3077 and hepatitis B chronicity is one of the most consistently replicated genetic findings in HBV research. A landmark study by An et al. 2011 in 1,742 Han Chinese⁴⁴ An et al. 2011 in 1,742 Han Chinese
A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance established that the A allele (protective) was associated with a more than doubled likelihood of HBV clearance (OR 2.41, p<0.001) and a 38% reduced risk of chronic infection (OR 0.62, p=0.001). A subsequent meta-analysis of eight studies by Zhang et al. 2013⁵⁵ meta-analysis of eight studies by Zhang et al. 2013
Association of the rs3077 and rs9277535 polymorphisms with HBV infection and spontaneous clearance; pooled analysis of Asian cohorts confirmed an additive dose-response: each copy of the protective A allele further reduces the odds of chronic HBV, with AA homozygotes showing an OR of 0.35 (65% risk reduction) relative to GG homozygotes.

The same signal shapes hepatitis B vaccine response⁶⁶ hepatitis B vaccine response
Standard HBV vaccination induces protective anti-HBs antibody titres ≥10 mIU/mL in >90% of recipients; the G allele at rs3077 is associated with impaired antibody production, making carriers more likely to be non-responders. A Japanese study of 278 healthcare workers found rs3077 was strongly associated with vaccine antibody response (OR 0.32, p=0.010) — GG carriers were disproportionately likely to fail to mount protective anti-HBs titres after standard vaccination. The finding replicated in Caucasian cohorts: Vermehren et al. identified a striking OR of 5.1 (CI 1.9–13.7) for HBV infection risk in European G-allele carriers, confirming the association extends beyond Asian populations.

The G allele frequency varies dramatically by ancestry: only ~17% in Europeans, ~30% in South Asians and Latinos, ~49% in Africans, and ~65% in East Asians — mirroring the global pattern of HBV endemicity and likely reflecting differential historical selection pressure from the virus.

Practical Actions

The clinical relevance of this variant depends on HBV exposure and vaccination status. For unvaccinated GG carriers, routine serology and consideration of enhanced vaccination protocols are the primary actions. For AG carriers, standard vaccination monitoring is appropriate. For those already vaccinated, checking post-vaccination anti-HBs titres is informative given the association with non-response. For those already chronically infected, the A allele at rs3077 predicts better HBsAg seroclearance during antiviral therapy — an important consideration for treatment planning with nucleot(s)ide analogues.

Interactions

The rs3077 signal is part of a broader HLA-DP haplotype. Its partner variant [rs9277535 | HLA-DPB1 3′ UTR — the beta-chain counterpart; commonly studied together with rs3077 as a two-SNP HLA-DP haplotype that additively predicts HBV outcomes], located in HLA-DPB1 (the beta chain gene adjacent to HLA-DPA1), independently tags HBV clearance and vaccine response. The CA haplotype (rs3077 A + rs9277535 A on the coding strand — i.e., plus-strand A at rs3077 + plus-strand A at rs9277535) is more strongly protective than either SNP alone (OR 0.57, CI 0.36–0.92 in the Indonesian replication study). This compound haplotype effect makes a strong case for profiling both variants together when assessing HBV susceptibility.